brilacidin

Brilacidin is a synthetic, non-peptidic small molecule designed as a mimetic of host defense proteins (HDPs), specifically defensins, which are part of the innate immune system. It acts primarily as an antibiotic by disrupting bacterial cell membranes, leading to rapid bacterial death and reducing the likelihood of resistance development. In addition to its antibacterial activity—especially against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA)—brilacidin exhibits broad-spectrum antiviral properties. Its antiviral mechanisms include direct virucidal activity and inhibition of viral entry by binding to heparan sulfate proteoglycans (HSPGs) on host cells. The drug also has immunomodulatory effects that can reduce inflammation and promote healing. Originally developed by PolyMedix and further advanced by Innovation Pharmaceuticals, brilacidin has been investigated in clinical trials for indications such as COVID‑19, skin and soft tissue infections, stomatitis, ulcerative proctitis, and other infectious or inflammatory conditions[1][2][3][4][5].

Brand names

Brilacidin-OM

Other names

BrilacidinaBrilacidineBrilacidinumBrilacidin tetrahydrochlorideBrilacidin-OcularBrilacidin-OMBrilacidin-Otic